Onconetix (ONCO) Gross Margin (2024 - 2026)
Onconetix (ONCO) posted quarterly Gross Margin of 280.74% for Q4 2025, up 18805.0% year-over-year from N/an in Q4 2024, and up 217.03% quarter-over-quarter from 88.55% in Q3 2025.
Onconetix (ONCO) Gross Margin (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Gross Margin for 2 consecutive years, with 280.74% the latest figure, recorded in Q4 2025.
- In Q4 2025, Gross Margin rose 18805.0% year-over-year to 280.74%; the TTM figure through Mar 2026 stood at 117.47% (up 6989.0% YoY), while the FY2025 annual figure was 105.49%, up 6368.0% from the prior year.
- Gross Margin rose to 280.74% in Q4 2025 per ONCO's latest filing, from 88.55% in the prior quarter.
- Across five years, Gross Margin topped out at 280.74% in Q4 2025 and bottomed at 14.29% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Onconetix | 1.45 Mn | -4.50 Mn | 4,303.00 | 25.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.13% |
| Mar 31, 2026 | -7.71% |
| Dec 31, 2025 | 280.74% |
| Sep 30, 2025 | 88.55% |
| Jun 30, 2025 | 66.20% |
| Mar 31, 2025 | 45.83% |
| Dec 31, 2024 | 92.70% |
| Sep 30, 2024 | 26.35% |
| Jun 30, 2024 | 14.29% |
| Mar 31, 2024 | 26.98% |